Figure 1
From: Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
AbTCR + co-stim T cells mediate antigen-specific responses in vitro and in vivo. (A) Schematic design of the AbTCR + co-stim T-cell. LDH release was measured as a proxy for T cell-mediated target cell lysis in peptide-loaded T2 cells (B) and HepG2 cells (C). A total of 20 HLA-A*02 presented, non-AFP related peptides (sequences in Methods) were used as control peptides (ctl peptides in B). (D) NSG mice were inoculated with HepG2 cells and treated intravenously with one dose of 5 × 106 T cells when tumors reached approximately 200 mm3, using the AbTCR + co-stim as an experimental arm and a CD19-targeting construct as control arms (n = 6 NSG mice/group). Efficacy was measured as the average volume of HepG2 subcutaneous tumors and the rate of animal survival. (E) Tumor infiltrating lymphocytes (TILs) in HepG2 subcutaneous tumors were analyzed by immunohistochemical staining for human CD3. Representative images are shown for one tumor of each group with two areas at 40 × magnification (left) and 1 × whole-mount (right). Scale bar in 40x, 100 μm. Quantification of human T cells in the tumors was performed by counting CD3 positive cells and total cells in different areas throughout the section. Each data point represents one tumor sample. Statistical significance indicated as *, p < 0.05; ***, p < 0.001; ****, p < 0.0001.
